XML 33 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaboration Agreements And Business Development Activities (Tables)
 9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Collaborative Revenues Under Collaboration Agreement
Revenues under the collaboration agreement with Ipsen were as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
License revenues$27,607 $25,139 $103,389 $81,246 
Collaboration services revenues7,211 12,956 28,196 81,576 
Total$34,818 $38,095 $131,585 $162,822 
Revenues under the collaboration agreement with Takeda were as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
License revenues$2,690 $20,078 $7,755 $23,476 
Collaboration services revenues3,661 2,656 11,148 10,815 
Total$6,351 $22,734 $18,903 $34,291 
License revenues under the collaboration agreement with Genentech were as follows (in thousands):
 Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Profits on U.S. commercialization$1,504 $1,743 $5,325 $5,697 
Royalty revenues on ex-U.S. sales$1,494 $1,576 $4,011 $3,309